- Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company aiming to develop immunotherapies as mono/combination treatments based on macrophage reprogramming technology.
- Enlivex's sole therapeutic is a late-stage immunotherapy, Allocetra, using early-apoptotic densely-packed cells to reprogram macrophages to a homeostatic state aiming to treat diseases and conditions associated with Sepsis, ARDS/COVID-19, and solid-tumors.
- Enlivex is a non-revenue producing biotechnology company with cash as of 3Q 2021 plus recent financings of $92M funding operations through Q1 2024 with revenues not projected until 2024-2025.
- Enlivex has a series of upcoming 2021 catalysts with the earliest being the Q1/Q2 2021 top-line data announcement from macrophage reprogramming for COVID-19 Phase 2 which is expected to provide a strong uplift.
- In summary, the author projects Enlivex Therapeutics Ltd. as a "buy" at a conservative 1-2 year price target of $15 (+36% upside).
For further details see:
Enlivex: Interesting Macrophage Reprogramming Science Targets $33B Sepsis Market